Suspension of trading
Valuation Cerevel Therapeutics Holdings, Inc.
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
23:00:00 31/07/2024 +03
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
Company Valuation: Cerevel Therapeutics Holdings, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Market Cap 1 | 2,108 | 4,773 | 4,928 | 7,659 |
| Change | - | 126.47% | 3.24% | 55.42% |
| Enterprise Value (EV) 1 | 1,757 | 4,226 | 4,405 | 6,964 |
| Change | - | 140.48% | 4.24% | 58.09% |
| P/E | -8.23x | -19.6x | -13.6x | -15.9x |
| PBR | 5.48x | 8.28x | 9.47x | 11.4x |
| PEG | 0.1x | 1.1x | -0.3x | -1.1x |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -12.3x | -19.7x | -12.1x | -15.8x |
| EV / EBIT | -12.2x | -19.4x | -12x | -15.6x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -2.013 | -1.65 | -2.324 | -2.671 |
| Distribution rate | - | - | - | - |
| Net sales | - | - | - | - |
| EBITDA 1 | -143.2 | -214.9 | -362.9 | -441.6 |
| EBIT 1 | -143.6 | -217.6 | -367.8 | -447.3 |
| Net income 1 | -152.1 | -225.3 | -351.5 | -432.8 |
| Net Debt 1 | -350.6 | -547.9 | -523.2 | -695.4 |
| Reference price 2 | 16.58 | 32.42 | 31.54 | 42.40 |
| Nbr of stocks (in thousands) | 127,124 | 147,236 | 156,244 | 180,634 |
| Announcement Date | 3/24/21 A | 3/1/22 A | 2/22/23 A | 2/27/24 A |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 8.19B | |
| 20.62x | 7.16x | 14.45x | 1.43% | 69.02B | |
| 37.68x | 9.86x | 30.11x | 0.04% | 66.32B | |
| -77.54x | 14.97x | -72.18x | -.--% | 27.66B | |
| 30.64x | 6.56x | 17.04x | -.--% | 26.54B | |
| -15.71x | 6.02x | -7.56x | -.--% | 25.84B | |
| 27.79x | 5.19x | 17.27x | -.--% | 20.4B | |
| 50.92x | 18.81x | 38.16x | 0.3% | 17.63B | |
| 1308.71x | 37.87x | 826.39x | -.--% | 15.15B | |
| 18.26x | 5.45x | 12.72x | -.--% | 14.65B | |
| Average | 155.71x | 12.43x | 97.38x | 0.2% | 29.14B | |
| Weighted average by Cap. | 83.82x | 10.53x | 52.90x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CERE Stock
- Valuation Cerevel Therapeutics Holdings, Inc.
Select your edition
All financial news and data tailored to specific country editions
